(Q37832125)

24 August 2017

1 reference

title

Polycystic ovary syndrome: etiology, pathogenesis and diagnosis (English)

1 reference

polycystic ovary syndrome

24 August 2017

0 references

0 references

1 reference

1 reference

4

Ricardo Azziz

1 reference

24 August 2017

1

Mark O Goodarzi

1 reference

24 August 2017

Daniel A Dumesic

2

1 reference

PubMed ID

21263450

24 August 2017

Gregorio Chazenbalk

series ordinal

3

1 reference

24 August 2017

25 January 2011

1 reference

Nature Reviews Endocrinology

24 August 2017

1 reference

24 August 2017

7

1 reference

24 August 2017

219-231

1 reference

24 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2010.217

24 August 2017

0 references

cites work

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

The prevalence and features of the polycystic ovary syndrome in an unselected population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Polycystic ovaries and associated clinical and biochemical features in young women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Androgen excess in women: experience with over 1000 consecutive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Ultrasound diagnosis of polycystic ovaries in women who have no symptoms of polycystic ovary syndrome is not associated with subfecundity or subfertility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Isolated polycystic morphology in ovum donors predicts response to ovarian stimulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Visually scoring hirsutism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Ultrasound examination of polycystic ovaries: is it worth counting the follicles?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Aromatase mRNA expression in individual follicles from polycystic ovaries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Insulin action in the normal and polycystic ovary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Local roles of TGF-beta superfamily members in the control of ovarian follicle development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Anti-Müllerian hormone: a new marker for ovarian function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Granulosa cells of polycystic ovaries: are they normal or abnormal?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Impact of obesity on the risk for polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Low body adiposity and high leptinemia in breast-fed infants born small-for-gestational-age

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

It's not how fat you are, it's what you do with it that counts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-{alpha}.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Regulation of gonadotropin secretion: implications for polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Neuroendocrine aspects of polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Polycystic ovary syndrome and its developmental origins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Prenatal testosterone excess programs reproductive and metabolic dysfunction in the female.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Early origins of polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Early Origins of polycystic ovary syndrome: hypotheses may change without notice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Circulating maternal testosterone concentrations at 18 weeks of gestation predict circulating levels of antimüllerian hormone in adolescence: a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Metabolic parameters in cord blood of newborns of women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Clinical review: Identifying children at risk for polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Polycystic ovary syndrome in adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

The inheritance of polycystic ovarian disease and a possible relationship to premature balding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Familial polycystic ovaries: a genetic disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Familial clustering in the polycystic ovarian syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Heritability of polycystic ovary syndrome in a Dutch twin-family study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

High prevalence of metabolic syndrome in first-degree male relatives of women with polycystic ovary syndrome is related to high rates of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Looking for polycystic ovary syndrome genes: rational and best strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Nonreplication of the type 5 17beta-hydroxysteroid dehydrogenase gene association with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6 17beta-hydroxysteroid dehydrogenase gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Family-based analysis of candidate genes for polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Oligoanovulation with polycystic ovaries but not overt hyperandrogenism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Metabolic features of the reproductive phenotypes of polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Effects of exercise and nutritional counseling in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Effect of bisphenol A on steroid hormone production in rat ovarian theca-interstitial and granulosa cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Gender difference in serum bisphenol A levels may be caused by liver UDP-glucuronosyltransferase activity in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Endocrine-disrupting chemicals: an Endocrine Society scientific statement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Consensus on infertility treatment related to polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

A macaque model for studying mechanisms controlling oocyte development and maturation in human and non-human primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Normal development and metabolic activity of preimplantation embryos in vitro from patients with polycystic ovaries.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

IVF versus ICSI in sibling oocytes from patients with polycystic ovarian syndrome: a randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

The chromosomal normality of unfertilized oocytes from patients with polycystic ovarian syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Oocyte quality in polycystic ovaries revisited: identification of a particular subgroup of women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Insulin resistance increases the risk of spontaneous abortion after assisted reproduction technology treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome patients undergoing gonadotropin therapy for in vitro fertilization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Insulin and messenger ribonucleic acid expression of insulin receptor isoforms in ovarian follicles from nonhirsute ovulatory women and polycystic ovary syndrome patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Polycystic ovary syndrome and oocyte developmental competence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Obstetric outcome in women with polycystic ovarian syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Birth weight in offspring of mothers with polycystic ovarian syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Low birth weight and later development of insulin resistance and biochemical/clinical features of polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Birth weight and age at menarche in patients with polycystic ovary syndrome or diminished ovarian reserve, in a retrospective cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

High prevalence of polycystic ovary syndrome in women born small for gestational age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute spons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Long-term health consequences of PCOS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Screening women with polycystic ovary syndrome for metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Endothelial dysfunction in PCOS: role of obesity and adipose hormones.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Clinical signs of androgen excess as risk factors for coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

[Menstrual cycle irregularity as a marker of cardiovascular risk factors at postmenopausal years]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Increased risk of depressive disorders in women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Depression in women with polycystic ovary syndrome: clinical and biochemical correlates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Insulin resistance and depressive symptoms in young adult males: findings from Finnish military conscripts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Screening for bipolar disorder in women with polycystic ovary syndrome: a pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Reproductive function and risk for PCOS in women treated for bipolar disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Longitudinal evaluation of reproductive function in women treated for bipolar disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Polycystic ovary syndrome and gynecological cancers: is there a link?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Polycystic ovary syndrome and endometrial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Prevalence of polycystic ovary syndrome and related disorders in mexican women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Polycystic ovary syndrome: an ancient disorder?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Correlates of increased lean muscle mass in women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Bone mineral density and body composition in lean women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Eating, exercise, and "thrifty" genotypes: connecting the dots toward an evolutionary understanding of modern chronic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Type 2 diabetes, cardiovascular disease, and the evolutionary paradox of the polycystic ovary syndrome: a fertility first hypothesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Metformin in the treatment of infertility in polycystic ovarian syndrome: an alternative perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Review: aromatase inhibitors for ovulation induction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.217

Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth.

31 March 2020

1 reference

12 December 2020

Regulation of ovarian follicular development in primates: facts and hypotheses

1 reference

12 December 2020

A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

1 reference

12 December 2020

Cellular mechanisms of insulin resistance in polycystic ovarian syndrome

1 reference

12 December 2020

Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes.

1 reference

12 December 2020

5alpha-reductase activity in women with polycystic ovary syndrome

1 reference

12 December 2020

Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome

1 reference

12 December 2020

Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome

1 reference

12 December 2020

Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity

1 reference

12 December 2020

Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing

1 reference

12 December 2020

Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome

1 reference

12 December 2020

The evaluation and management of hirsutism*1

1 reference

12 December 2020

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women

1 reference

12 December 2020

Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance

1 reference

12 December 2020

Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone

1 reference

12 December 2020

Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome

1 reference

12 December 2020

Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study

1 reference

12 December 2020

Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: are the molecular mechanisms distinct from type 2 diabetes?

1 reference

12 December 2020

A mechanism for the suppression of estrogen production in polycystic ovary syndrome.

1 reference

12 December 2020

Hyperthecosis: an inheritable form of polycystic ovarian disease

1 reference

12 December 2020

Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid

1 reference

12 December 2020

Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries

1 reference

12 December 2020

Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women

1 reference

12 December 2020

The outcome of in vitro fertilization and embryo transfer in women with polycystic ovary syndrome failing to conceive after ovulation induction with exogenous gonadotropins

1 reference

12 December 2020

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

12 December 2020

Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls

1 reference

12 December 2020

Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy

1 reference

12 December 2020

Pregnancy in infertile PCOD patients. Complications and outcome

1 reference

12 December 2020

A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.

1 reference

12 December 2020

Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.

1 reference

12 December 2020

Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives

1 reference

12 December 2020

Molecular defects of insulin action in the polycystic ovary syndrome: possible tissue specificity.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2010.217

1 reference

24 August 2017

1 reference

PubMed ID

21263450